ReviewCerebral radiation necrosis: A review of the pathobiology, diagnosis and management considerations
Introduction
Conventional radiation therapy (CRT) and stereotactic radiation therapy (SRT) represent important components of comprehensive strategies to treat patients with brain tumors. Three time-limited forms of radiation toxicity have been described: acute, early delayed and delayed long-term radiation-induced neurotoxicity. Acute toxicity occurs during or immediately after radiation treatment; early delayed neurotoxicity occurs up to 12 weeks following treatment; and delayed neurotoxicity develops and evolves from 3 months to a few years following treatment (Fig. 1).1 The various manifestations of delayed radiation neurotoxicity include radiation necrosis (RN), radiation leukoencephalopathy, radiation myelopathy, and, in the peripheral nervous system, plexus or nerve root lesions.2, 3 In 1930, Fischer and Holfelder described the first case of delayed RN following radiation therapy of a basal cell carcinoma of the scalp.4 In 1950, Lowenberg-Scharenberg described the pathological occurrence of amyloid degeneration in cerebral parenchyma following X-ray irradiation.5 These initial descriptions were followed by numerous additional reports, series and reviews that have since documented RN as a major complication of therapeutic central nervous system (CNS) irradiation.6, 7, 8, 9, 10, 11 Similar effects have also been observed as a complication of radiation therapy to tumors of the paranasal sinuses, nasopharynx, middle ear, parotid and lacrimal glands, in which cases the CNS is incidentally involved in the treatment field(s).12, 13
The exact incidence of intracranial RN remains undetermined, although it ranges from 5–50%, depending on the modality of treatment, the dose delivered, the duration a patient is followed clinically and with neuroimaging, the neuroimaging criteria used, and whether clinical signs and symptoms are present.14 Kramer et al. initially attempted to determine the incidence of RN by reviewing the literature, but could not come to a conclusion because of a lack of data regarding the total treated population.15 Several factors continue to complicate a detailed analysis of the actual rates of RN, including alternate modalities of radiation therapy, the fact that the published literature comprising mostly class III evidence, that not all reported studies have histopathological confirmation of their findings, and that variable treatment parameters have been used for radiation delivery (including dose, fractionation schedules, treatment times, radiation field arrangements and volume).9 Additionally, most of the studies took place prior to the availability of modern neuro-imaging, making it difficult to calculate radiation parameters.9, 16, 17 The use of adjuvant chemotherapy has further confounded the analysis of data. In addition, the exact population being diagnosed and treated has also been variably reported in the literature as the number of patients treated rather than those at risk (survivors), which may underestimate risk, thus making it difficult to ascertain a precise incidence for RN.
In this review we present a comprehensive review of intracranial RN after therapeutic brain irradiation, with a focus on RN developing in patients after radiation therapy of a brain tumor. We discuss the pathobiology of RN, its clinical features, its diagnosis, and potential strategies for its management, including the benefit and toxicity profiles of these therapies.
Section snippets
Pathobiology of radiation necrosis
Radiation-induced damage can occur with radiation doses as low as 50 Gy, however the radiation dose is directly proportional to the risk of brain injury.18 In cases where fractionated therapy is used, larger fractional doses correspond to a greater risk of subsequent RN.19 Chemotherapy may potentiate the risk of brain injury, and was first reported in children who survived treatment for leukemia.20 Lai et al. reported a series of five patients, treated with whole brain radiotherapy and high-dose
Determinants of radiation necrosis
Patients vary in their individual responses to radiation therapy. Some may develop severe adverse reactions, while others treated for similar pathologies in similar locations with comparable radiation doses and administration protocols do not. The extent of these adverse reactions are a limiting factor in the total radiation dose delivered, modulating the success of radiation therapy, both with respect to tumor response and toxicity. The precise cause of this variability in response remains
Conventional radiation therapy (CRT)
The reported incidence of cerebral RN has fluctuated over the years. In 1975, Marsa et al.76 reported an incidence of 15%, while in 1986, Hohweiler et al.77 noted a rate of 14% following CRT protocols. In addition to focal patterns of RN, both groups observed more diffuse changes, such as periventricular white matter changes, consistent with patterns of diffuse radiation induced injury. These changes increased with age, cerebral volume irradiated, dose and interval between imaging and
Diagnosis
The dilemma in the diagnosis of RN lies in the fact that tumor recurrence and necrosis may have similar manifestations, both in clinical presentation and radiological appearance. However, management of these two entities may be diametrically opposed, with recurrent tumors requiring intervention to stop growth whereas RN may follow a more benign management path.
Management considerations
Spontaneous resolution of cerebral RN may occur, but in many patients symptoms develop and can be progressive, necessitating treatment to provide symptomatic relief.157 In a few patients, the relentless nature of the pathology may necessitate surgical resection of the necrotic mass.9, 158 It is paramount that the patient understands the nature of the pathology being treated, and the consequences and sequelae of the condition – as well as the various treatments that may be used and their
Considerations for patient evaluation and management
We have classified considerations for patient management into four ascending categories based on clinical and radiological findings (Fig. 5). Recommendations for clinical and imaging follow-up are detailed above, in the section entitled “Observation and steroids.” One common strategies to initially perform clinical and imaging follow-up at short intervals (for example, every 6–12 weeks for 2–4 cycles), slowly increasing over time (every 4–6 months for 2–4 cycles until the imaging lesion is
Conclusion
Radiation therapy is an important treatment modality in patients with brain tumors, but local toxicities complicate this treatment. A subset of patients receiving radiotherapy as adjuvant brain tumor therapy will ultimately develop RN. Significant risk factors for developing RN are the total dose of radiotherapy delivered, the fractionated dose, and the addition of concurrent chemotherapy.190 Although modern imaging techniques have improved the specificity and sensitivity of radiographic
Conflict of Interest
There are no conflicts of interest to report for any of the authors.
Role in the Study
Conception and Design: Rahmathulla, Marko, Weil
Acquisition of Data: Rahmathulla, Marko
Analysis and Interpretation of the Data: Rahmathulla, Marko, Weil
Drafting the article: Rahmathulla, Weil
Critically revising the article: Rahmathulla, Marko, Weil
Final manuscript review and approval: Rahmathulla, Marko, Weil
Study supervisor: Weil
Acknowledgements
We wish to thank the Melvin Burkhardt chair in Neurosurgical Oncology and the Karen Colina Wilson Research Endowment within the Burkhardt Brain Tumor and Neuro-oncology Center at the Cleveland Clinic Foundation for additional support and funding.
References (218)
- et al.
Therapeutic irradiation and brain injury
Int J Radiat Oncol Biol Phys
(1980) - et al.
Cerebral radionecrosis following the treatment of parotid tumours: a case report and review of the literature
Int J Oral Maxillofac Surg
(1999) - et al.
Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume
Int J Radiat Oncol Biol Phys
(1981) - et al.
The late effects of radiation on the blood brain barrier
Int J Radiat Oncol Biol Phys
(1986) - et al.
Does variability in normal tissue reactions after radiotherapy have a genetic basis–where and how to look for it?
Radiother Oncol
(2002) The progression rate of late radiation effects in normal tissue and its impact on dose-response relationships
Radiother Oncol
(1989)- et al.
Prognostic factors for acute and late skin reactions in radiotherapy patients
Int J Radiat Oncol Biol Phys
(1996) - et al.
Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706
Int J Radiat Oncol Biol Phys
(1991) - et al.
The genomics revolution and radiotherapy
Clin Oncol (R Coll Radiol)
(2007) Radiosensitivity in Fanconi’s anemia patients
Radiother Oncol
(2002)
Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer?
Am J Hum Genet
Prediction of normal-tissue tolerance to radiotherapy from in-vitro cellular radiation sensitivity
Lancet
Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer
Int J Radiat Oncol Biol Phys
Cellular radiosensitivity and complication risk after curative radiotherapy
Radiother Oncol
Predictive tests of response to radiotherapy. Assessment and perspectives in 1997
Cancer Radiother
Genetic markers for prediction of normal tissue toxicity after radiotherapy
Semin Radiat Oncol
Genetic predictors of adverse radiotherapy effects: the Gene-PARE project
Int J Radiat Oncol Biol Phys
Radiosensitivity, radiogenomics and RAPPER
Clin Oncol (R Coll Radiol)
Towards genetic prediction of radiation responses: ESTRO’s GENEPI project
Radiother Oncol
Genetic variants and normal tissue toxicity after radiotherapy: a systematic review
Radiother Oncol
The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy
Int J Radiat Oncol Biol Phys
Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer
Int J Radiat Oncol Biol Phys
Adverse effects of brain irradiation correlated with MR and CT imaging
Int J Radiat Oncol Biol Phys
Intensity-modulated radiation therapy
Int J Radiat Oncol Biol Phys
From IMRT to IGRT: frontierland or neverland?
Radiother Oncol
Brachytherapy for recurrent malignant astrocytoma
Int J Radiat Oncol Biol Phys
Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma
Int J Radiat Oncol Biol Phys
External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G–82-2
Int J Radiat Oncol Biol Phys
Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas
Int J Radiat Oncol Biol Phys
Long-term results of brachytherapy with temporary iodine-125 seeds in children with low-grade gliomas
Int J Radiat Oncol Biol Phys
Cerebral radiation necrosis
Neurologist
Anticoagulation for radiation-induced neurotoxicity revisited
J Neurooncol
Complications of radiation therapy on the brain and spinal cord
Semin Neurol
Cerebral radiation necrosis simulating a brain tumor
J Neurosurg
Amyloid degeneration of the human brain following X-ray therapy
J Neuropathol Exp Neurol
The morphologic effects of radiation administered therapeutically for intracranial gliomas. A postmortem study of 25 cases
Cancer
Radiation necrosis after treatment of solitary intracranial metastases
Neurosurgery
Necrosis of the brain due to radiation therapy; clinical and pathological observations
J Neurol Neurosurg Psychiat
Late bilateral temporal lobe necrosis after conventional radiotherapy
Neurol Med Chir
Cerebral necrosis following radiotherapy of extracranial neoplasms
Ann Neurol
Progressive white matter destruction following irradiation of an extracranial neoplasm
Ann Neurol
Dosimetric considerations in the diagnosis of radiation necrosis of the brain. Radiation damage to the nervous system. A delayed therapeutic hazard
Radiation effect and tolerance of the central nervous system
The hazards of therapeutic iradiation of the central nervous system
Clin Neurosurg
Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence
J Neurol
Radiation dose-volume effects in the brain
Int J Radiat Oncol Biol Phys
Encephalopathy in acute leukaemia associated with methotrexate therapy
Arch Dis Child
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study
Neurology
Encephalomyelopathy following high-dose BCNU therapy
Cancer
Multifocal leukoencephalopathy in adult leukemia: histologic features and etiologic considerations
Acta Neuropathol
Cited by (156)
A Novel Multimodal Approach to Refractory Brain Metastases: A Case Report
2024, Advances in Radiation OncologyComparing Surgery with Stereotactic Radiation Alone for Newly Diagnosed Brain Metastases
2024, World NeurosurgeryModeling gamma knife radiosurgical toxicity for multiple brain metastases
2023, Radiotherapy and OncologyTo study the protective effect of Huangqi Baihe Granules on Radiation brain injury based on network pharmacology and experiment
2023, Journal of Ethnopharmacology